Healthtech Solutions Inc. (HLTT) Enters Precision Oncology Market with Acquisition of Varian Biopharmaceuticals
Ability to tailor diagnostics, therapeutics to specific patients is key to precision medicine Global precision oncology market projected to grow at CAGR of 9.9% over the next eight years, will reach $99.7 billion by 2027 Varian Bio making significant headway in development of two preclinical experimental cancer drugs Healthtech Solutions (OTC: HLTT) is making a strong statement with its most recent acquisition. HLTT acquired Varian Biopharmaceuticals, a precision oncology company developing novel therapeutics for the treatment of cancer —and with the acquisition, the company is making its entry into the precision cancer care market (https://nnw.fm/gLdfb). “Precision medicine is a concept that…